- Home
- BMEA vs DOMH Comparison
BMEA vs DOMH Comparison
Compare BMEA & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- DOMH
- Stock Information
- Founded
- BMEA 2017
- DOMH 1967
- Country
- BMEA United States
- DOMH United States
- Employees
- BMEA N/A
- DOMH N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- DOMH Biotechnology: Pharmaceutical Preparations
- Sector
- BMEA Health Care
- DOMH Health Care
- Exchange
- BMEA Nasdaq
- DOMH Nasdaq
- Market Cap
- BMEA 65.8M
- DOMH 71.2M
- IPO Year
- BMEA 2021
- DOMH N/A
- Fundamental
- Price
- BMEA $1.81
- DOMH $5.70
- Analyst Decision
- BMEA Strong Buy
- DOMH
- Analyst Count
- BMEA 10
- DOMH 0
- Target Price
- BMEA $22.30
- DOMH N/A
- AVG Volume (30 Days)
- BMEA 5.2M
- DOMH 322.3K
- Earning Date
- BMEA 07-30-2025
- DOMH 08-07-2025
- Dividend Yield
- BMEA N/A
- DOMH 5.63%
- EPS Growth
- BMEA N/A
- DOMH N/A
- EPS
- BMEA N/A
- DOMH N/A
- Revenue
- BMEA N/A
- DOMH $24,891,000.00
- Revenue This Year
- BMEA N/A
- DOMH N/A
- Revenue Next Year
- BMEA N/A
- DOMH N/A
- P/E Ratio
- BMEA N/A
- DOMH N/A
- Revenue Growth
- BMEA N/A
- DOMH 630.80
- 52 Week Low
- BMEA $1.29
- DOMH $0.83
- 52 Week High
- BMEA $13.07
- DOMH $13.58
- Technical
- Relative Strength Index (RSI)
- BMEA 44.35
- DOMH 63.00
- Support Level
- BMEA $2.24
- DOMH $4.90
- Resistance Level
- BMEA $3.08
- DOMH $5.59
- Average True Range (ATR)
- BMEA 0.40
- DOMH 0.50
- MACD
- BMEA -0.03
- DOMH 0.11
- Stochastic Oscillator
- BMEA 25.07
- DOMH 82.16
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.